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Wrch-1 is an atypical Rho family small GTPase with roles in migration, epithelial cell morphogenesis,
osteoclastogenesis, and oncogenic transformation. Here, we observed rapid relocalization of Wrch-1 from the
plasma membrane upon serum stimulation. Studies revealed a requirement for serum-stimulated tyrosine
phosphorylation of Wrch-1 at residue Y254 within its C-terminal membrane targeting domain, mediated by the
nonreceptor tyrosine kinase Src. Genetic or pharmacological loss of Src kinase activity blocked both phos-
phorylation and relocalization of Wrch-1. Functionally, Y254 was required for proper Wrch-1 modulation of
cystogenesis in three-dimensional culture, and the phospho-deficient mutant, Y254F, was enhanced in Wrch-
1-mediated anchorage-independent growth. Mechanistically, C-terminal tyrosine phosphorylation and subse-
quent relocalization of Wrch-1 downregulated its ability to interact with and activate its effectors by decreasing
active Wrch-1-GTP, perhaps by altering proximity to a GEF or GAP. Phospho-deficient Wrch-1(Y254F)
remained at the plasma membrane and GTP bound and continued to recruit and activate its effector PAK, even
upon serum stimulation. In contrast, a phospho-mimetic mutant, Y254E, was constitutively endosomally
localized and GDP bound and failed to recruit PAK unless mutated to be constitutively active/GAP insensitive.
C-terminal tyrosine phosphorylation thus represents a new paradigm in posttranslational control of small
GTPase localization, activation, and biological function.
Rho family proteins are Ras-related small GTPases that
regulate cytoskeletal organization and dynamics, cell adhesion,
motility, trafficking, proliferation, and survival (20). They func-
tion as tightly regulated molecular switches, cycling between an
active GTP-bound state and an inactive GDP-bound state.
Rho GTPases are also regulated by their subcellular localiza-
tion, directed by sequences and posttranslational modifica-
tions, such as an isoprenoid lipid attached permanently to their
C-terminal membrane targeting regions (1), and a second sig-
nal, such as a polybasic region or a palmitate fatty acid (34).
Rho-guanine nucleotide dissociation inhibitors (RhoGDIs)
bind prenyl groups and sequester Rho proteins from mem-
branes (19, 42). Interaction of the GTP-bound proteins with
their downstream effectors at specific locations then elicits
their biological functions.
Wrch-1, also designated RhoU or Wrch1, is an atypical
member of the Cdc42 subgroup of Rho GTPases that induce
the formation of actin microspikes and filopodia. Although it
shares 57% sequence identity with Cdc42 and 61% sequence
identity with its closest relative, Chp/Wrch-2, Wrch-1 shares
only partially overlapping localization and effector interactions
with them and is regulated in a distinct manner. Like Cdc42,
Wrch-1 activates PAK1 and JNK (13, 44), induces formation of
filopodia (34, 35), and both morphological (8) and growth
transformation in multiple cell types (5, 8). Wrch-1 also regu-
lates focal adhesion turnover (13, 31), negatively regulates tight
junction kinetics (8), plays a required role in epithelial morpho-
genesis (8), and modulates osteoclastogenesis (9, 10, 31).
Initially discovered as a Wnt-responsive gene capable of
phenocopying Wnt morphological transformation (43, 44),
Wrch-1 is transcriptionally regulated by Wnt (36), RANKL
(10), and STAT3 (36), and it is upregulated in some cancers
but downregulated in others (22). Thus, modulation of Wrch-1
activity at the level of expression is a common event. However,
because it is a GTP-binding protein, a more dynamic regula-
tion of Wrch-1 activity is also required.
Wrch-1 is thought to be largely GTP bound due to a high
intrinsic exchange rate (2, 39), and no regulatory GEFs or
GAPs have yet been identified. However, a putative dominant
negative mutant of Wrch-1, T63N, does not behave like the
wild type (34), so at least one GEF may be important to
activate Wrch-1. Also, mutationally activated (Q107L, analo-
gous to Q61L in Ras or Cdc42) Wrch-1 is more active than
wild-type Wrch-1 (5, 8, 9, 31, 44), so one or more GAPs remain
to be identified. Finally, Wrch-1 contains a negative regulatory
46-amino-acid N-terminal extension (39), and interaction with
Grb2 or phospholipase C1 (35, 39) may help to relieve auto-
inhibition (39).
In addition to these modes of regulation, Wrch-1 function
requires posttranslational lipid modification of its C-terminal
membrane targeting domain. Unusually, Wrch-1 is not preny-
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lated but is modified by palmitoylation (5), a dynamically reg-
ulated lipid modification (29) required for both its subcellular
localization and biological activities (5, 8). Lacking a prenyl
group, Wrch-1 does not bind RhoGDI (4). Both prenylation
and the polybasic region of Cdc42 are required for its proper
localization and function (46), but the identities of additional
signals governing Wrch-1 are unknown.
There is increasing evidence that C-terminal serine/threo-
nine phosphorylation of small GTPases near the isoprenoid
moiety is required for both their localization and specific func-
tions. In response to protein kinase C (PKC)-mediated phos-
phorylation of Ser181 in its C-terminal membrane targeting
domain, K-Ras4B translocates from the plasma membrane to
the mitochondria, where it then promotes apoptosis instead of
proliferation (6). RalA is a target of Aurora A kinase-mediated
phosphorylation at Ser194 (47) and PP2A A-mediated de-
phosphorylation (7); phosphorylation of this site depletes
RalA from the plasma membrane (27). Rap1 is phosphory-
lated on Ser180 by protein kinase A (26, 32), and RhoA local-
ization and modulation of cell spreading and migration is reg-
ulated by PKA-mediated phosphorylation on Ser188 (17, 25),
which promotes its binding to RhoGDI (17). PKC (28, 33)
and ROCK (33) stimulate phosphorylation of Rnd3/RhoE,
which results in translocation, and PKC-mediated phosphory-
lation is required for Rnd3 to modulate the Rho/ROCK path-
way (28). TC10 is phosphorylated by cyclin-dependent kinase 5
on Thr197, which regulates its association with lipid rafts, a
requirement for its ability to modulate insulin-stimulated
GLUT4 translocation (30). Thus, there is significant evidence
for the functional importance of C-terminal serine/threonine
modification of small GTPases.
Here, we sought to determine which C-terminal elements in
addition to palmitoylation contribute to the regulation of
Wrch-1 subcellular localization and biological activity. The
minimal C-terminal membrane targeting sequence of Wrch-1
does not contain a suitable serine or threonine residue but
contains a potentially phosphorylatable tyrosine residue. Fur-
ther, subcellular localization is often dynamically regulated by
external signals such as those supplied by serum factors that
stimulate engagement of growth factor receptor tyrosine ki-
nases and their associated nonreceptor tyrosine kinase part-
ners (41). In this report, we describe our discovery that serum
stimulates Src-mediated tyrosine phosphorylation of Wrch-1
and its translocation from the plasma membrane and that a
specific tyrosine residue in the C-terminal membrane targeting
domain of Wrch-1 regulates its subcellular localization, GTP/
GDP-binding status, effector activation, and biological activi-
ties. Thus, we have identified C-terminal tyrosine phosphory-
lation as a novel mechanism for regulation of small GTPase
activity.
MATERIALS AND METHODS
Molecular constructs. Mammalian expression constructs for green fluorescent
protein (GFP)-tagged and hemagglutinin (HA) epitope-tagged human Wrch-1
(wild-type [WT] and Q107L) have been described previously (5). Phospho-
deficient Wrch-1(Y254F) and phospho-mimetic Wrch-1(Y254E) were generated
by site-directed mutagenesis in both WT and Q107L backgrounds. The GFP-
fusion protein of the C-terminal 9 amino acids (the “9-aa tail”) of Wrch-1
expressed from pEGFP has been described previously (5). An additional GFP
fusion containing the C-terminal 19 amino acids (19-aa tail) was generated by
site-directed mutagenesis in the same manner. All sequences were verified by the
Genome Analysis Facility at UNC-CH. GFP-PAK-PBD and GST-PAK-PBD
were kind gifts from Channing Der (UNC-CH) and Keith Burridge (UNC-CH),
respectively. WT Src, constitutively active Src(Y528F), and kinase-deficient
Src(K297R) were expressed from the pUSE vector, all from Upstate Biotech-
nology. Bacterial expression constructs and purification of GST-Wrch-1 protein
have been described previously (38).
Cell culture, transfections, and retroviral infection. H1299 non-small cell lung
cancer (NSCLC) cells were grown in Dulbecco’s modified Eagle medium (high
glucose; DMEM-H; GIBCO/Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Sigma) and 1% penicillin-streptomycin (P/S) (“complete culture
medium”) and maintained in 5% CO2 at 37°C. H1299 cells were transfected with
expression constructs encoding Wrch-1, Src, or PAK-PBD proteins by using
TransIT-LT1 (Mirus) according to the manufacturer’s instructions. For localiza-
tion assays, cells were transfected transiently and used 24 h after transfection.
For selection of stably expressing cell lines, cells were grown in complete medium
supplemented with the appropriate antibiotic for 5 to 7 days, after which 50
colonies were pooled for use.
MDCKII cells, generously provided by Robert Nicholas (UNC-CH), were
grown as above and supplemented with 1% nonessential amino acids (NEAA;
Invitrogen) (“complete medium”). MDCKII cell lines stably expressing Wrch-1
were generated by retroviral infection. Retrovirus was collected following CaCl2-
mediated transfection of pBabe-HAII-puro, pVPack-Gag/Pol, and pVPack-
Ampho (Stratagene) expression vectors into 293T cells. Cells were infected by
exposure to retroviral supernant containing 8 g/ml of Polybrene (American
Bioanalytical) and maintained in puromycin for 10 days, after which the colonies
were pooled for use.
SYF mouse embryo fibroblast cells (MEFs) genetically lacking Src, Yes, and
Fyn, or YF cells lacking Yes and Fyn but retaining Src (23), were grown in
complete culture medium as described above. Cells were transiently transfected
with constructs encoding HA-Wrch-1 proteins by using TransIT-LT1 (Mirus)
according to the manufacturer’s instructions.
Fluorescence, immunofluorescence, confocal microscopy, and localization as-
says. Cells were transfected transiently with pEGFP-Wrch-1 expression vectors
or pEGFP-PAK-PBD as indicated above and grown in complete medium for
24 h. The cells were then either grown further overnight in complete medium
(“basal conditions”), or serum starved overnight in 0% serum (“serum starved”),
or serum starved overnight in 0% serum and then stimulated for 2, 5, or 15 min
with fresh serum-containing complete medium (“starved and stimulated”). For
some experiments, cells were treated for 1 h with the Src family kinase inhibitor
SU6656 (Sigma) or dimethyl sulfoxide vehicle prior to serum stimulation. Fol-
lowing incubation with Alexa 647-transferrin (Molecular Probes), cells were fixed
and then visualized for GFP-Wrch-1 (green) or transferrin (red). HA-Wrch-1
was visualized by staining with a primary anti-HA antibody (Covance) and a
secondary anti-mouse antibody conjugated to Alexa 647 (Invitrogen). Confocal
microscopy was performed on an Olympus Fluoview 500 laser scanning confocal
imaging system, configured with an IX81 fluorescence microscope fitted with a
PlanApo 60 oil objective.
Antibodies and immunoblot analysis. Western blot analyses were carried out
as described previously (8). Briefly, cells were lysed in magnesium lysis buffer
(MLB) containing 1 protease inhibitor cocktail (Roche) with or without 100
M pervanadate, lysates were cleared by centrifugation, and protein concentra-
tions were determined using the DC Lowry protein assay (Bio-Rad). Twenty
micrograms of protein for each sample, prepared in 5 Laemmli sample buffer,
was resolved by using 12% SDS-PAGE. Proteins were transferred to polyvinyl-
idene difluoride membranes (PVDF; Millipore), blocked overnight in 3% fish
gelatin, and then probed for Wrch-1 by a 1-h incubation with the following
primary antibodies: anti-HA epitope (HA.11; Covance), antiphosphotyrosine
(pY100 from Cell Signaling Technologies [CST] or pY20 from Santa Cruz
Biotechnology), anti-GFP (JL8; Clontech), anti-PAK1/2/3 (CST), anti-phospho-
PAK1(Thr423)/-PAK2(Thr402) (CST), anti-Pyk2 (50), or anti-phospho-
Pyk2(Tyr402) (Biosource). Anti--actin (Sigma) was used to demonstrate equiv-
alent loading. Washed membranes were incubated in anti-mouse or anti-rabbit
IgG–horseradish peroxidase (HRP; Amersham Biosciences) or anti-mouse
kappa light chain–HRP (Zymed), washed again, and developed using Super-
Signal West Dura extended duration substrate (Pierce).
Immunoprecipitation. H1299 cells expressing GFP- or HA-tagged Wrch-1
were lysed in MLB with protease inhibitor, with or without pervanadate, as
described above, at 24 h after transfection. Lysates were precleared with protein
A/G beads (Santa Cruz) and then incubated overnight with anti-GFP or anti-HA
antibody. After 18 h, the protein-antibody complexes were recovered using
protein A/G beads. Beads were collected and washed with MLB and resus-
pended in Laemmli sample buffer, the precipitated proteins were resolved on
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SDS-PAGE, and immunoblot analysis for phosphotyrosine was performed as
described above.
In vitro tyrosine kinase assay. Recombinant Wrch-1 protein was used as a
substrate for purified Src kinase in a standard in vitro kinase assay. Bacterially
expressed GST-Wrch or GST alone was incubated for 40 min at 30°C with or
without 0.8 g of purified recombinant Src protein (Upstate Biotechnology) in
Src kinase reaction buffer (100 mM Tris [pH 7.2], 125 mM MgCl2, 25 mM MnCl2,
2 mM EGTA, 100 M Na3VO4, and 2 mM dithiothreitol) containing [-32P]ATP
(10 Ci per reaction mixture). Reactions were terminated by the addition of 4
sample buffer and then heated at 95°C for 5 min. Protein samples were separated
by 10% SDS-PAGE and visualized by Coomassie blue staining. Incorporation of
radiolabel was determined by audioradiography.
Anchorage-independent growth transformation assay. Single-cell suspensions
of MDCK cells (3.5  103 cells per 35-mm dish) were suspended in 0.4% agar
(BD Biosciences) in complete medium and layered on top of 0.6% agar as
described previously (8). After 14 days, colonies were stained with 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) after count-
ing of small colonies (6 to 15 cell diameters) and large colonies (15 cell
diameters), and the average number of each type of colony on triplicate dishes
was quantified. A one-way analysis of variance (ANOVA) and Tukey’s post hoc
test were performed; P values of 0.01 were considered significant.
Epithelial morphogenesis cyst formation assay. MDCKII cells stably express-
ing HA-tagged Wrch-1 proteins were allowed to form cysts in three-dimensional
(3D) collagen matrices as described previously (8). Briefly, monodispersed
MDCKII cells were allowed to grow and form multicellular cyst structures on
collagen I gels for 10 days, when the cultures were treated with collagenase type
VII (C-2399; Sigma). Cyst structures were fixed and permeabilized, then incu-
bated with fluorescent Texas Red-phalloidin (Molecular Probes) and mounted
for imaging on an Olympus Fluoview confocal microscope as indicated above.
Multiple x-y and x-z scans were acquired for each 3D collagen gel. We have
shown previously that tightly regulated endogenous Wrch-1 activity is critical for
proper cystogenesis on 3D collagen I matrices in these cells (8). In each of three
replicate experiments, 25 multicellular cyst structures were evaluated for each
Wrch-1-expressing cell line and binned into one of the following three groups:
normal cysts (cysts containing a single lumen) or one of two groups of abnormal
cysts (either cysts containing no lumen or cysts containing multiple lumens), as
we have done previously (8). Student’s t test was performed to determine sig-
nificance; P values of 0.01 were considered significant.
Wrch-1 activation assay. H1299 cells were transiently transfected with either
pCGN vector only or pCGN vectors encoding HA-Wrch-1, HA-Wrch-1(Y254F),
HA-Wrch-1(Y254E), HA-Wrch-1(Q107L), HA-Wrch-1(Q107L/Y254F), or HA-
Wrch-1(Q107L/Y254E), by using TransIT LT1 as described above. Cells were
serum starved overnight, or serum starved and then serum stimulated for 2, 5, or
15 min as described above. Cells were then washed twice with ice-cold phos-
phate-buffered saline (pH 7.4) and lysed in MLB as described above. Equal
volumes were removed from each lysate for total protein analysis. To each lysate,
glutathione-agarose beads containing 40 g of GST-p21-activated kinase (PAK)
GTPase-binding domain fusion protein (GST-PAK-PBD) were added and incu-
bated at 4°C for 60 min with rocking. Agarose-GST-PAK-PBD and associated
Wrch-1 was pelleted and washed three times with 500 l wash buffer (25 mmol/
liter Tris [pH 7.5], 40 mmol/liter sodium chloride, and 30 mmol/liter magnesium
chloride). Final pellets were resuspended in 1 protein sample buffer and re-
solved on SDS-PAGE. HA-Wrch-1 was detected using anti-HA antibody (Co-
vance).
RESULTS
Wrch-1 rapidly relocalizes from the plasma membrane in
response to serum stimulation. We have shown previously that
the atypical Rho family small GTPase Wrch-1 localizes to both
plasma membrane and internal compartments, including en-
dosomal membranes (5). Because localization of other pro-
teins, including some Rho GTPases, can be directed by exter-
nal stimuli, such as serum-stimulated engagement of growth
factor receptors, and is therefore dynamically regulated, we
sought to determine whether Wrch-1 localization was similarly
regulated. We serum starved overnight H1299 NSCLC cells
transiently expressing enhanced GFP (EGFP)-tagged Wrch-1
(designated GFP-Wrch-1) and stimulated them with serum for
15 min. Under basal or serum-starved conditions (Fig. 1, left
and middle columns), Wrch-1 was localized both to the plasma
membrane and to endosomal membranes (marked by trans-
ferrin; middle row). In contrast, upon serum stimulation,
Wrch-1 underwent rapid loss from the plasma membrane (Fig.
1, right column) but continued to localize to endosomes. Time-
lapse video taken over the same time course confirmed relo-
calization of Wrch-1 from the plasma membrane (see Movie
S1 in the supplemental material). These data indicate that
Wrch-1 subcellular localization is both dynamic and regulated
by upstream growth signals.
Relocalization is dependent on the presence of a tyrosine at
position 254 in the Wrch-1 C-terminal membrane targeting
domain. We had previously determined that the carboxy-
terminal 9 amino acids of Wrch-1 are sufficient for its proper
subcellular localization (5) and that mutation of the palmi-
toylated cysteine residues therein results in cytosolic accu-
mulation (5). Within this sequence of WWKKYCCFV, the
single tyrosine at residue 254 (Y254) stood out. We hypothesized
that Y254 becomes tyrosine phosphorylated in response to serum
stimulation and that this phosphoryation event modulates Wrch-1
subcellular localization and activity.
We therefore generated a Y3F mutation at position 254 [des-
ignated Wrch-1(Y254F)]. The putatively phospho-deficient
Wrch-1(Y254F) was resistant to serum-stimulated relocalization:
the plasma membrane-localized pool of Wrch-1(Y254F) re-
mained on the plasma membrane even after serum stimulation
(Fig. 2A; see also Movie S2 in the supplemental material).
Further, cells expressing this nonphosphorylatable mutant dis-
played an exaggeratedly rounded phenotype under basal se-
rum-containing conditions, similar to that seen in serum-
starved cells expressing only WT Wrch-1 (Fig. 2A) and
consistent with a serum-dependent event altering both Wrch-1
phosphorylation and cytoskeletal organization.
These results were also consistent with our hypothesis that
Wrch-1 becomes tyrosine phosphorylated on Y254 in response
to serum stimulation and that this phosphorylation event is
FIG. 1. Wrch-1 rapidly relocalizes upon serum stimulation. H1299
NSCLC cells transiently transfected to express GFP-Wrch-1 were
grown in complete culture medium, then serum starved overnight, or
first serum starved and then serum stimulated. Prior to serum stimu-
lation, the treated cells were incubated for 1 h with AlexaFluor 647-
labeled transferrin to mark endosomal compartments. After 15 min of
serum stimulation, cells were fixed and then subjected to confocal
microscopy for visualization of GFP-Wrch-1 (green) or transferrin
(red). Bars, 20 m.
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responsible for serum-stimulated relocalization of Wrch-1. To
confirm that Wrch-1 was tyrosine phosphorylated at Y254, we
immunoprecipitated Wrch-1 proteins from H1299 cells with
anti-HA antibody and probed for phosphotyrosine. Wrch-1 but
not Wrch-1(Y254F) was detected by anti-phosphotyrosine an-
tibody following serum stimulation (Fig. 2B), confirming that
Wrch-1 is tyrosine phosphorylated and suggesting that Y254 is
the major site of serum-stimulated phosphorylation.
Interestingly, we also determined that basal subcellular lo-
calization of Wrch-1 requires less targeting information than
does either tyrosine phosphorylation or serum-stimulated re-
localization. The last 9 amino acids in the C terminus of
Wrch-1 are sufficient for proper basal localization of Wrch-1
(5). Surprisingly, this short sequence (the 9-aa tail) (Fig. 3A)
was not sufficient to support either tyrosine phosphorylation
(Fig. 3B) or serum-stimulated relocalization (Fig. 3C). We
speculated that 9 amino acids was an insufficient length to allow
binding of the kinase. We generated an additional GFP-fusion
protein comprising 19 amino acids of the Wrch-1 C terminus (the
19-aa tail), which still contained only a single tyrosine residue
(Fig. 3A), which was sufficient both for tyrosine phosphorylation
(Fig. 3B) and for relocalization (Fig. 3C). Interestingly, expression
of the 19-aa tail resulted in altered cell size and shape, suggesting
that it may sequester proteins important for regulating the actin
cytoskeleton. Together, these data indicate that relocalization of
Wrch-1 requires additional sequences compared to basal local-
ization, perhaps to allow efficient kinase binding to the region
encompassing Y254.
Src can phosphorylate Wrch-1, and Src tyrosine kinase ac-
tivity is required for both tyrosine phosphorylation and se-
rum-stimulated relocalization of Wrch-1. The nonreceptor ty-
rosine kinase Src, which transmits signaling from several
serum-responsive growth factor receptor tyrosine kinases, has
many substrates, not all of which have been defined clearly. We
speculated that Src could phosphorylate Wrch-1 on Y254, and
indeed we found that the Src family kinase inhibitor SU6656
FIG. 2. Wrch-1 is tyrosine phosphorylated on Y254 in response to serum, and this phosphorylation is required for serum-stimulated relocal-
ization. (A) Nonphosphorylatable Wrch-1(Y254F) is resistant to serum-stimulated relocalization. H1299 cells expressing either GFP-Wrch-1 or
GFP-Wrch-1(Y254F) were grown, treated, and evaluated as described for Fig. 1. Bars, 20 m. (B) Serum-stimulated tyrosine phosphorylation of
Y254. H1299 cell lysates from cells expressing empty vector (VO), HA-Wrch-1, or HA-Wrch-1(Y254F) were incubated with anti-HA antibody.
Immunoprecipitated (IP) Wrch-1 was detected by immunoblotting (IB) with anti-HA, and phosphotyrosine (p-Tyr) on Wrch-1 was detected by
immunoblotting with antiphosphotyrosine antibody. The bands above and below the Wrch-1 band represent immunoglobulin heavy chain and light
chains, respectively. Apparent molecular masses are shown (in kilodaltons).
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effectively blocked tyrosine phosphorylation of Wrch-1 (Fig.
4A). At the concentration that we used (5 M), SU6656 is
reported to inhibit the related tyrosine kinases Src, Yes, Fyn,
and Lyn (3). Therefore, we analyzed Wrch-1 phosphorylation
in MEF cells from mice genetically deficient in Src, Yes, and
Fyn (SYF; Src/) (Lyn is restricted to hematopoietic cells) or
deficient in Yes and Fyn but not Src (YF; Src	/	). Wrch-1 was
tyrosine phosphorylated in YF MEFs expressing Src but not in
SYF MEFs lacking Src, indicating that Src is required for
tyrosine phosphorylation of Wrch-1 (Fig. 4B). These data in-
dicate that Src functions upstream of Wrch-1 to mediate its
tyrosine phosphorylation. To address whether Src kinase en-
zymatic activity is required, we cotransfected H1299 cells with
HA-Wrch-1 or HA-Wrch-1(Y254F) along with either consti-
tutively active or kinase-deficient Src. Wrch-1 was tyrosine
phosphorylated in the presence of kinase-active Src(Y528F)
but not kinase-deficient Src(K297R), and the Y254 residue of
Wrch-1 was required for this phosphorylation, as Wrch-
1(Y254F) was not phosphorylated regardless of Src kinase
activity (Fig. 4C). These data support a requirement for Src
kinase activity in order for Wrch-1 to become tyrosine phos-
phorylated on Y254. To address whether the phosphorylation
is direct or indirect, we performed an in vitro kinase assay with
recombinant purified Src and GST-Wrch-1. Wrch-1 was di-
rectly phosphorylated by Src in vitro (Fig. 4D), consistent with
the possibility that it may be phosphorylated directly in vivo.
Having established that Wrch-1 could be a substrate of Src
kinase activity, and that the Y254 residue of Wrch-1 that is
required for serum-stimulated relocalization is also the major
site of Src-stimulated phosphorylation, we wished to test
whether Src kinase activity is required for serum-stimulated
relocalization of Wrch-1. We serum-starved cells expressing
GFP-Wrch-1, treated them with SU6656 (5 M) for 1 h, then
serum-stimulated them as above. SU6656 prevented Wrch-1
relocalization in response to serum stimulation (Fig. 4E). Col-
lectively, these results indicate that Src tyrosine kinase activity
FIG. 3. The C-terminal 19 amino acids of Wrch-1 are sufficient for Wrch-1 to become tyrosine phosphorylated and to be relocalized in response
to serum. (A) Schematic of the 19-aa and 9-aa tails. Shown are the GFP-tagged sequences extended with 9 or 19 amino acids of the C terminus
of Wrch-1. Y254 is the only tyrosine residue present in each fusion protein. (B) Serum-stimulated tyrosine phosphorylation of the C-terminal 19
but not 9 amino acids of Wrch-1. H1299 cell lysates expressing either empty vector (GFP), GFP-Wrch-1 (FL), GFP fused to the 19-aa tail of
Wrch-1, or GFP fused to the 9-aa tail ofWrch-1 were incubated with anti-GFP antibody to immunoprecipitate Wrch-1. Immunoprecipitated (IP)
Wrch-1 was then detected by immunoblotting (IB) with anti-GFP antibody, and phosphotyrosine Wrch-1 was detected by immunoblotting with
anti-phosphotyrosine antibody. (C) The C-terminal 19 amino acids of Wrch-1 are sufficient for serum-stimulated relocalization. H1299 cells as in
panel B were grown, treated, and evaluated as described for Fig. 1. Bars, 20 m.
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FIG. 4. Src activity is required in vivo for tyrosine phosphorylation of Wrch-1. (A) The Src family tyrosine kinase inhibitor SU6656 prevents
Wrch-1 tyrosine phosphorylation in response to serum stimulation. H1299 cells expressing HA-Wrch-1 were serum starved overnight, treated with
5 M SU6656 for 1 h, and serum stimulated for 5 min. Lysates were subjected to immunoprecipitation (IP) with anti-HA to retrieve HA-Wrch-1,
followed by immunoblotting (IB) for Wrch-1 (anti-HA) or phosphotyrosine (anti-p-Tyr). Bands above and below the Wrch-1 band represent the
Ig heavy chain and light chain, respectively. (B) Endogenous Src is required for serum-stimulated Wrch-1 tyrosine phosphorylation. SYF/ MEFs
(MEFs lacking Src, Yes, and Fyn) and YF/ MEFs (MEFs retaining Src but lacking Yes and Fyn) expressing either HA-Wrch-1 or nonphos-
phorylatable HA-Wrch-1(Y254F) were starved overnight and then serum stimulated for 5 min. The resulting cell lysates were probed for
phosphotyrosine on Wrch-1 as described for panel A. (C) Src kinase activity is required for tyrosine phosphorylation of Wrch-1. H1299 cells were
cotransfected with empty vector, HA-Wrch-1, or nonphosphorylatable HA-Wrch-1(Y254F) along with either empty vector, kinase-active Src (Src
Y528F), or kinase-deficient Src (Src K297R). Phosphotyrosine on Wrch-1 was detected as shown in panel A. (D) Src directly phosphorylates
Wrch-1 in vitro. Purified recombinant GST-Wrch-1 protein was incubated with purified recombinant Src tyrosine kinase protein and [32P]ATP.
Total protein was detected by Coomassie blue staining, and [32P]ATP incorporation was detected by autoradiography. (E) Inhibition of Src kinase
with SU6656 blocks serum-stimulated relocalization of Wrch-1. H1299 cells expressing GFP-Wrch-1 or nonphosphorylatable GFP-Wrch-1(Y254F)
were grown in complete culture medium (basal) and then either serum starved overnight (serum starved) or first serum starved and then serum
stimulated for 15 min, with or without 1 h of pretreatment with 5 M SU6656. Cells were visualized as for Fig. 1 for Wrch-1 (green) or transferrin
(red). Bars, 20 m.
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is required for both the tyrosine phosphorylation and relocal-
ization of Wrch-1. Whether Src is a direct or indirect mediator
of Wrch-1 phosphorylation in vivo remains uncertain.
Phosphorylatable residue Y254 regulates Wrch-1-mediated
transformation. Correct subcellular localization is critical to
regulate the biological functions of Rho GTPases (18). We
hypothesized that tyrosine phosphorylation, which alters
Wrch-1 subcellular localization, also likely alters at least some
of its biological functions. Both wild-type and constitutively
active Wrch-1(107L) are capable of inducing anchorage-inde-
pendent growth transformation, such as colony formation in
soft agar (5, 8), and endogenous Wrch-1 is required for correct
epithelial cell morphogenesis (8). A nonpalmitoylated mutant
of Wrch-1 that fails to localize correctly to the plasma mem-
brane is unable to modulate either of these biological functions
(5, 8). Therefore, we generated polarizable MDCKII epithelial
cell lines stably expressing either HA-Wrch-1 or phospho-
deficient HA-Wrch-1(Y254F) in both the WT and 107L
backgrounds and confirmed that they expressed equivalent
amounts of each protein (Fig. 5A, bottom panel). We then
quantitated soft agar colony formation after 14 days of anchor-
age-independent growth. Cells expressing either of the non-
phosphorylatable Y254F mutants formed a significantly in-
creased number of large colonies (15 cells in diameter) in
soft agar compared to phosphorylatable Wrch-1 (Fig. 5A).
These results indicate that tyrosine phosphorylation of Y254
represents a negative regulatory control of Wrch-1 biological
activity.
Phosphorylatable residue Y254 regulates Wrch-1-mediated
epithelial morphogenesis. Several Rho family small GTPases
are required for cystogenesis in a 3D environment (11). In
particular, Cdc42 is thought to be a master regulator of lumen
development in tube and cyst structures, by virtue of its ability
to regulate the Par6/atypical PKC (aPKC) polarity complex
(11). Wrch-1 also binds Par6/aPKC, and a precise balance of
endogenous Wrch-1 is also required for proper cystogenesis
in a 3D environment, because either too little or too much
Wrch-1 causes disruption of the formation of normal, single-
lumen-containing, hollow cyst structures (8), and Cdc42 is un-
able to compensate for loss of Wrch-1. We therefore examined
the effect of Wrch-1 tyrosine phosphorylation on this crucial
Wrch-1-mediated function. MDCKII cells expressing phos-
phorylatable or phospho-deficient (Y254F) Wrch-1 were
seeded in a matrix of collagen I, and cyst structures formed
after 10 days were imaged with Texas Red-phalloidin. Consti-
tutively phospho-deficient Wrch-1(Y254F) disrupted epithelial
cell morphogenesis, as shown by a greatly decreased propor-
tion of normal cysts containing a single lumen (Fig. 5B), and
this disruption was greater than the disruption induced by
phosphorylatable Wrch-1, whether in a WT or in a constitu-
tively GTP-bound and active (107L) background (Fig. 5B).
Together, these data indicate a requirement for the Y254 res-
idue for proper function of at least two important biological
activities of Wrch-1 and suggest that tyrosine phosphorylation
at this site may be an important mechanism to precisely control
Wrch-1 activity.
Wrch-1 interacts with its effector PAK at the plasma mem-
brane, where it is GTP bound and active, but not at endo-
somes, where it is GDP bound and inactive. The lower biolog-
ical activity displayed by wild-type Wrch-1 compared to the
phospho-deficient Wrch-1 mutant Y254F that remains on the
plasma membrane suggested that Wrch-1 is less able to inter-
act with its effectors when it is endosomally localized than
when it is localized to the plasma membrane. We therefore
evaluated the ability of Wrch-1 to interact with its best-vali-
dated effector, PAK, at each of these locations, by utilizing a
GFP-tagged form of the GTPase-binding domain of PAK
(GFP-PAK-PBD). To test whether the same conditions of
serum stimulation that cause Wrch-1 to become phosphory-
lated at Y254 and to relocalize away from the plasma mem-
brane also decreased its interactions with PAK-PBD, we co-
transfected H1299 cells with GFP-PAK-PBD and HA-tagged
Wrch-1 or vector and observed their localization under con-
ditions of serum starvation or stimulation. Representative
images are shown in Fig. 6A, and the distribution of GFP-
PAK-PBD primary localization to cytosol, plasma mem-
brane, or endomembrane compartments under each condi-
tion was quantitated as depicted in Fig. 6B. As expected, in
cells expressing only empty vector, GFP-PAK-PBD was dis-
tributed diffusely throughout the cell (Fig. 6A, green, and 6B,
top left panel.) In contrast, in cells expressing HA-Wrch-1,
GFP-PAK-PBD was recruited to specific membrane sites in a
serum-dependent manner. In serum-starved cells, Wrch-1 was
localized to both plasma membrane and internal membranes,
as expected (Fig. 6A, red), whereas PAK-PBD (green) dis-
played overlapping localization with Wrch-1 (merged image;
yellow) only at the plasma membrane. These results indicate
that only the plasma membrane-localized pool, but not the
internally localized pool, of Wrch-1 was able to recruit PAK-
PBD (localized to plasma membrane in 78% of cells) (Fig. 6B).
Upon serum stimulation, Wrch-1 redistributed away from
the plasma membrane in a time-dependent manner as seen
previously, such that by 15 min it was absent from the
plasma membrane and localized predominantly at internal
membranes. Under these conditions, PAK-PBD was not
recruited to specific sites but was again distributed diffusely
throughout the cytosol (83%), consistent with our hypothesis
that tyrosine phosphorylation and relocalization of Wrch-1
from the plasma membrane decrease its ability to interact with
and recruit effectors.
Because PAK-PBD binds preferentially to the active, GTP-
bound form of Wrch-1, these results indicate that Wrch-1 is
active at the plasma membrane but not at internal membranes.
To confirm that Wrch-1 would still be able to bind PAK-PBD
at internal membranes if it were active and GTP bound
there, we examined the ability of a constitutively activated,
GAP-insensitive mutant of Wrch-1 [Wrch-1(Q107L)] to re-
cruit PAK-PBD. As expected, the 107L mutant still relocalized
upon serum stimulation and still recruited PAK-PBD (Fig.
6A), even to internal membranes (85%) (Fig. 6B). Thus, the
inability of WT Wrch-1 to recruit PAK-PBD following serum
stimulation is not because PAK-PBD is simply unable to access
endosomal compartments or to interact with tyrosine-phos-
phorylated Wrch-1.
Our observation that Wrch-1 recruited PAK-PBD to the
plasma membrane but not to internal membranes further sup-
ports our hypothesis that tyrosine phosphorylation at Y254 and
subsequent loss from the plasma membrane downregulates
Wrch-1 activity. To further test this possibility, we examined
recruitment of PAK-PBD by the nonphosphorylatable mutant
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FIG. 5. Phosphorylation at Y254 negatively regulates Wrch-1-mediated biological functions. (A) Phosphorylatable tyrosine residue Y254
negatively regulates anchorage-independent growth. MDCKII cell lines were generated to stably express Wrch-1 proteins as indicated. Equivalent
expression was confirmed by immunoblotting with anti-HA. -Actin was used as a loading control. Cells were seeded into soft agar for
anchorage-independent colony formation and grown for 14 days, then stained with MTT. Small colonies (6 to 15 cell diameters across) and large
colonies (15 cell diameters across) were quantified. Bar graphs indicate three independent experiments carried out in triplicate. One-way
ANOVA and Tukey’s post hoc tests were used to determine the significance of differences between numbers of colonies arising from cells
expressing Wrch-1 with or without the Y254F mutation, in either the WT or constitutively activated (107L) backgrounds. **, P  0.001.
(B) Phosphorylatable tyrosine residue Y254 negatively regulates epithelial cell morphogenesis. MDCKII cells expressing Wrch-1 as in panel A were
seeded into 3D collagen matrices and allowed to form cysts for 10 days. Cyst structures were evaluated and quantified according to whether they
contained one lumen (normal; single lumen), more than one lumenal area (multilumen), or no lumen at all. Bars are the averages of three
independent experiments for each cell line, with standard deviations. The significance of differences between numbers of normal cysts with single
lumens in cells of different backgrounds was determined as described for panel A. *, P  0.01.
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Wrch-1(Y254F), in which the plasma membrane-bound pool
remains on the plasma membrane and fails to relocalize in
response to serum. As expected, the Y254F mutant continued
to recruit PAK-PBD to the plasma membrane after serum
stimulation (Fig. 6B, middle left panel; 84% plasma membrane
localization) even in the absence of a concurrent constitutively
activating mutation 107L (Fig. 6A). This result indicates that
retention of a pool of Y254F at the plasma membrane is
FIG. 6. Wrch-1 is GTP bound and active and recruits its effector PAK1 at the plasma membrane but not at endosomes. (A) Serum stimulation
decreases recruitment of GFP-PAK-PBD to the plasma membrane by WT but not phospho-deficient Y254F Wrch-1. H1299 cells coexpressing
GFP-PAK-PBD along with vector or Wrch-1 proteins were grown, treated, and evaluated as described for Fig. 1, except images were taken at
multiple time points as shown. GFP-PAK-PBD signal is green and HA-Wrch-1 is red. Overlapping localization (merge; yellow) demonstrates
recruitment of GFP-PAK-PBD by Wrch-1. Bars, 20 m. (B) Quantitation of GFP-PAK-PBD subcellular distribution before and after serum
stimulation. For each condition depicted with representative images in panel A, 50 cells from each of three independent experiments were
evaluated for their subcellular distribution of GFP-PAK-PBD and quantified according to whether GFP-PAK-PBD localized primarily to the
cytosol, the plasma membrane, or endosomal compartments. Results are presented graphically as the percentage of total cells counted in which
the primary localization of GFP-PAK-PBD was identified as the specific compartment indicated. Bars represent the averages of three independent
experiments for each cell line, with standard deviations.
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sufficient to abrogate C-terminal phosphorylation-mediated
downregulation of Wrch-1 activity and to retain some Wrch-1
in an active conformation.
Finally, if phosphorylation of Wrch-1 at Y254 is sufficient
for relocalization and subsequent downregulation of Wrch-1
activity and effector interaction, then a phospho-mimetic
mutation should impair plasma membrane binding and in-
stead confer constitutive internal localization and poor ef-
fector interaction. Consistent with this, a phospho-mimetic
Y254E mutant was indeed largely excluded from the plasma
membrane, localized to internal membranes, and failed to re-
cruit PAK-PBD (Fig. 6A), which remained mostly cytosolic
FIG. 6—Continued.
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(83% [Fig. 6B]) unless Wrch-1(Y254E) was constitutively
GTP bound by virtue of a concurrent 107L mutation, in which
case it was able to recruit PAK-PBD to its internal membrane
location (Fig. 6A and B). These results also corroborate our
evidence suggesting that localization regulates Wrch-1 GTP-
binding status and that effector interaction of tyrosine-phos-
phorylated Wrch-1 is impaired as a consequence of decreased
GTP binding rather than of decreased access to effector pools.
In order to confirm these results biochemically, we per-
formed pull-down assays to detect the effects of serum stimu-
lation on active Wrch-1-GTP under conditions where subcel-
lular localization is irrelevant. PAK-PBD binds preferentially
to active, GTP-bound Wrch-1 whether tagged by GFP (Fig. 6)
or by GST (Fig. 7). We therefore transfected H1299 cells with
empty vector or vectors encoding HA-tagged Wrch-1 proteins
and treated them exactly as for the GFP-PAK-PBD localiza-
tion assays depicted in Fig. 6. Cells were then lysed and incu-
bated for 1 h with either purified GST or purified GST-PAK-
PBD coupled to glutathione-agarose beads. The resulting
protein complex was pulled down by centrifugation, washed,
eluted off the beads, resolved by SDS-PAGE, and immuno-
blotted for the active, GTP-bound HA-Wrch-1 that was pulled
down by interaction with GST-PAK-PBD. GST alone pulled
down no Wrch-1 (data not shown), nor did GST-PAK-PBD
pull down anything detectable by anti-HA antibody in the
absence of HA-Wrch-1 (Fig. 7, vector panel). As predicted by
the recruitment results from Fig. 6, GST-PAK-PBD pulled
down Wrch-1 quite strongly under conditions when Wrch-1
localizes to the plasma membrane (Fig. 7, WT and Y254F, 0
min). In contrast, GST-PAK-PBD pulled down almost none of
the Wrch-1 expected to be excluded from the plasma membrane
(WT, 15 min; all Y254E) (Fig. 7). Similarly, by 5 min of serum
stimulation, GST-PAK-PBD still pulled down Y254F robustly,
but the amount of WT Wrch-1 pulled down was dramatically
decreased (Fig. 7), consistent with the loss of WT but not Y254F
from the plasma membrane. Taken together, these results sup-
port that serum stimulation of phosphorylation of Wrch-1 at
Y254 causes its translocation from the plasma membrane and
that the internal membrane pool is inactive.
Serum-stimulated tyrosine phosphorylation and relocaliza-
tion of Wrch-1 decreases its activation of downstream effectors
in a Y254-dependent manner. The decrease in Wrch-1/PAK
effector interaction seen upon serum-stimulated tyrosine phos-
phorylation and subsequent relocalization of Wrch-1 strongly
implies that Wrch-1 activates this effector preferentially at the
plasma membrane and that loss from this compartment im-
pairs effector activation. PAK-PBD contains the GTPase-bind-
ing domain but is not the full-length PAK kinase effector of
Wrch-1. Further, active Wrch-1 has been shown to stimulate
autophosphorylation and activation of both the serine/threo-
nine kinase PAK1 (44) and the nonreceptor tyrosine kinase
Pyk2 (34). Therefore, we tested whether the same conditions
that relocalized Wrch-1 and decreased active Wrch-1-GTP
also altered activation of these two kinases that are immediate
downstream effectors of Wrch-1. Immunoblot analysis showed
robust phosphorylation at the autophosphorylation sites of
both PAK (Fig. 8A) and Pyk2 (Fig. 8B) in the presence of
Wrch-1 WT or Y254F but not Y254E prior to serum stimula-
tion, consistent with their interactions with PAK-PBD. Indeed,
levels of both phospho-PAK1 and -Pyk2 were markedly de-
creased in the presence of phospho-mimetic Wrch-1(Y254E)
and did not change regardless of serum stimulation. Similarly,
serum decreased autophosphorylation of PAK and PYK2 in
the presence of WT Wrch-1 (
95% and 38% decrease, respec-
tively), whereas Y254F conferred resistance to the decrease
(
15% and no decrease, respectively) (Fig. 8). Cells expressing
FIG. 7. Serum stimulation decreases active Wrch-1-GTP. To pull down active Wrch-1-GTP with GST-PAK-PBD, H1299 cells were transiently
transfected with pCGN vector or vector encoding HA-tagged Wrch-1 proteins, then treated as for Fig. 6. Resulting cell lysates were incubated with
GST-PAK fusion protein attached to glutathione-agarose beads. The Wrch-1/GST-PAK-PBD complex was collected by centrifugation, washed,
eluted from the beads, and resolved by SDS-PAGE. Wrch-1 was detected by immunoblotting with anti-HA antibody. (Upper panels) Pull down
followed by immunoblotting (GTP-Wrch-1); (lower panels) immunoblot of input total Wrch-1 available for pull down in the samples.
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empty vector were resistant to such a decrease (Fig. 8). Taken
together, our results are consistent with a model in which C-
terminal tyrosine phosphorylation downregulates Wrch-1 activity,
perhaps by decreasing interactions with a putative GEF or by
bringing it into proximity with an internally localized GAP.
DISCUSSION
We have shown here that the atypical Rho family small
GTPase Wrch-1 undergoes serum-stimulated Src-mediated ty-
rosine phosphorylation at residue Y254 in its C-terminal mem-
brane targeting domain, a modification that dynamically alters
its subcellular localization by promoting relocalization from
the plasma membrane. We also showed that Y254 is the major
site of phosphorylation and that mutation of Y254 to a non-
phosphorylatable phenylalanine residue (Y254F) prevents re-
localization of the plasma membrane pool, remains GTP
bound, enhances recruitment of the GTPase-binding domain
of the Wrch-1 effector PAK1 (PAK-PBD), and enhances
Wrch-1-mediated effects on growth transformation and on epi-
thelial morphogenesis in 3D culture. In contrast, both serum-
stimulated WT Wrch-1 and phospho-mimetic Y254E are re-
FIG. 8. Serum-stimulated Wrch-1 tyrosine phosphorylation results in decreased Wrch-1 effector activation. (A) Serum stimulation results in
decreased autophosphorylation of PAK1. Cells treated as described for Fig. 7 were probed for total PAK with an anti-PAK1/2/3 antibody or for
active phospho-PAK with an anti-phospho(Thr423)-PAK1/phospho(Thr402)-Pak2 antibody. (B) Serum stimulation results in decreased Pyk2
autophosphorylation. Cells treated as for panel A were probed for total Pyk2 with anti-Pyk2 antibody and for phospho-Pyk2 with anti-
phospho(Tyr402)-Pyk2 antibody. Densitometry was performed using ImageJ software. Phosphoprotein was normalized to total protein in each
lane, and the percent phosphorylation shown represents phosphorylation compared to no (0 min) serum stimulation.
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stricted from the plasma membrane and are inactive, failing to
recruit PAK-PBD or to activate the effector kinases PAK or Pyk2
unless mutationally activated to be GAP insensitive (Q107L) and
therefore constitutively active. These results indicate that C-ter-
minal tyrosine phosphorylation of Wrch-1 may be important for
downregulation of its biological activities, and they provide evi-
dence supporting a potential mechanism whereby loss of interac-
tion with an unidentified plasma membrane-associated GEF or
increased association with a novel endosomally localized Wrch-1
GAP turns off previously active Wrch-1-GTP.
Our results demonstrate that Wrch-1 is GTP bound and
active at the plasma membrane, where it is capable of recruit-
ing and activating downstream effectors such as PAK1 and
Pyk2. In contrast, serum-stimulated, Src-dependent phosphor-
ylation at Y254 results in loss of Wrch-1 from the plasma
membrane and loss of activity, and the endosomal pool of
Wrch-1 is inactive. That the constutively active, GAP-insensi-
tive mutant Q107L remains capable of effector recruitment at
endosomes even when targeted there by the C-terminal phos-
pho-mimetic mutation Y254E indicates that phosphorylation-
mediated relocalization does not decrease Wrch-1 effector ac-
tivation simply by removing Wrch-1 from its relevant effectors,
at least some of which are still present at endosomes. For
example, the well-validated Wrch-1 effector PAK is not only
present at endosomes but is recruited and activated preferentially
there by Chp/Wrch-2 in response to tumor necrosis factor alpha
(12). Instead, our results support a model in which loss of Wrch-1
from the plasma membrane pool upon C-terminal phosphoryla-
tion at Y254 actively promotes its deactivation, since the major
location is then the endosomal pool, which is not active.
Relocalization from the plasma membrane may decrease
interaction of Wrch-1 with a plasma membrane-localized GEF
or enhance its interaction with an endosomally localized GAP.
No GEFs or GAPs for Wrch-1 have been identified, although
both are presumed to exist. It is possible that known Cdc42-
activating GEFs such as the FGD family, Tuba, Asef, or In-
tersectin may promote Wrch-1 activity at the plasma mem-
brane, although these tend to be activated by growth factors or
serum, whereas Wrch-1 is inactivated upon serum stimulation.
On the other hand, endosomal GAPs, such as p50RhoGAP
(40) and ARAP1 (14, 49), have been identified for other Rho
family GTPases, but it is not known whether they promote
GTP hydrolysis on Wrch-1. Other mechanisms of endosomal
translocation and subsequent deactivation are well-docu-
mented for receptor tyrosine kinases (RTKs). Upon autophos-
phorylation and activation following growth factor stimulation,
many RTKs become ubiquitinated and undergo relocalization
to the endosomal compartment, which attenuates their signal-
ing (15, 16). Additionally, ubiquitination of the small GTPase
H-Ras has been shown to promote its endosomal trafficking
and thereby to attenuate its signaling through the Raf-MEK-
extracellular signal-regulated kinase pathway (21). We have
observed that Wrch-1 is also ubiquitinated but that this mod-
ification does not appear to grossly alter its localization (data
not shown). Thus, our present data best support the model of
C-terminal phosphorylation of Wrch-1 leading to its down-
regulation by decreasing proximity to one or more GEFs
and/or enhancing proximity to one or more GAPs.
Accumulating evidence suggests that phosphorylation of the
C-terminal membrane targeting domains on small GTPases
combines with other sequences and posttranslational modifi-
cations to dynamically regulate the localization and function of
these proteins. To date, all the phosphorylation sites so iden-
tified, whether in Ras or Rho GTPases, have been Ser/Thr
residues just upstream of C-terminal farnesyl or geranylgeranyl
isoprenoid modifications (6, 17, 25–28, 30, 33). However, the
atypical Rho family GTPase Wrch-1 is neither modified by
isoprenylation nor possesses cognate serine or threonine resi-
dues. Instead, our study provides the first report of direct
regulation of Rho family GTPase subcellular localization and
function by tyrosine phosphorylation of its membrane target-
ing domain. Although Cdc42 has been reported to be tyrosine
phosphorylated by Src upon epidermal growth factor stimula-
tion (45), this phosphorylation occurs at residue Y64 within the
switch II region rather than in the Cdc42 C terminus, which
lacks any tyrosine residue. Whether tyrosine phosphorylation
of Cdc42 alters its subcellular localization was not explored,
but it was reported to promote binding of Cdc42 to RhoGDI.
However, Wrch-1 is not modified by an isoprenoid, a feature
required for binding of RhoGDI (42), and does not interact
with RhoGDI (4). Thus, tyrosine phosphorylation of Wrch-1
and Cdc42 occurs on distinct domains and has distinct conse-
quences. Chp/Wrch-2, the closest relative of Wrch-1, is also
palmitoylated and unprenylated (12), but, like Cdc42, Chp
lacks a tyrosine residue near its C terminus. This is perhaps not
entirely surprising, as many closely related isoforms of small
GTPases differ from each other mostly in their membrane
targeting domains, possibly to provide signaling diversity.
Wrch-1 tyrosine phosphorylation at Y254 occurs only two
residues away from the critical palmitoylation site C256, raising
the question of whether one modification sterically hinders the
other. It is clear that tyrosine phosphorylation of Wrch-1 does
not require prior palmitoylation, as even a nonpalmitoylatable
Cys3Ser mutant becomes tyrosine phosphorylated upon se-
rum stimulation (data not shown). Indirect evidence suggests
that this phosphorylation can occur simultaneously with pal-
mitoylation: phosphorylation results in an increased associa-
tion with internal membranes, whereas an inability to be palmi-
toylated results in a complete lack of Wrch-1 membrane
association (5). Taken together, these results suggest that ty-
rosine phosphorylation normally occurs on palmitoylated
Wrch-1.
We have shown here that Wrch-1 tyrosine phosphorylation
requires Src and that Src can directly phosphorylate Wrch-1 in
vitro. Although Y254, the major residue for tyrosine phosphor-
ylation, does not occur in the context of a known Src kinase
consensus site, and algorithms such as NetPhos or ScanSite do
not predict its phosphorylation by Src, there is currently no
reliable predictor of whether a given protein is in fact a sub-
strate for Src in vivo. Even enolase, a commonly used positive
control for Src phosphorylation, does not contain a known Src
consensus site. However, many tyrosine kinases require phos-
phorylation themselves in order to be active, and this activating
or priming phosphorylation step may be accomplished in cis or
in trans. Therefore, other than direct phosphorylation of
Wrch-1 by Src, another possibility is that Src activity promotes
binding to Wrch-1 and/or activation of another tyrosine kinase
that can phosphorylate it. Whether Wrch-1 is a direct or an
indirect downstream target of Src-mediated phosphorylation in
cells remains to be determined.
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Recent studies have suggested several context-dependent
functional connections between Wrch-1 and Src that are likely
to be pertinent regardless of whether the connection is direct
or indirect. In osteoclasts, Wrch-1 colocalizes with Src in po-
dosomes, and increased Wrch-1 activity perturbs the podo-
some belt (31). Thus, Src-mediated tyrosine phosphorylation
of Wrch-1 could contribute to the dynamic regulation of
podosome formation and assembly. In addition, Wrch-1
negatively regulates macrophage colony-stimulating factor
(M-CSF)-stimulated osteoclast migration (9), and Src has re-
cently been shown to be activated in osteoclasts downstream of
M-CSF stimulation (48). Therefore, M-CSF may promote
osteoclast migration by activating Src, to then downregulate
Wrch-1 through tyrosine phosphorylation on Y254. In contrast
to osteoclasts, where it decreases migration, Wrch-1 increases
the migration of fibroblasts (13), where it is localized to focal
adhesions (31) and regulates their assembly. Src and several of
its substrates are major components of focal adhesions. In
PAE cells, Wrch-1 but not Cdc42 requires Src to induce for-
mation of filopodia (34), but it is unknown whether Src is
required for an effect on Wrch-1 itself or on a downstream
target not shared with Cdc42.
We have observed that Y254, the major site of Src-medi-
ated tyrosine phosphorylation, negatively regulates Wrch-1-
mediated anchorage-independent growth and epithelial cell
morphogenesis, because mutation to the nonphosphorylat-
able Y254F conferred greater activity on Wrch-1 than the
wild-type tyrosine residue. Thus, Src-mediated tyrosine phos-
phorylation at Y254 may normally act as a brake for Wrch-1
function. Although Src is often thought of simply as an onco-
gene that leads inexorably to cellular dedifferentiation, it is
clear that it can exert dual functions. For example, Src serves
dual functions during epithelial cell morphogenesis in Dro-
sophila melanogaster, where it both antagonizes E-cadherin-
mediated cell adhesion and simultaneously stimulates E-cad-
herin transcription (37). Similarly, if Src modulates Wrch-1
through opposing functions, then proper cycling between the
phosphorylated and the unphosphorylated state of Wrch-1 is
likely to be required for the correct final outcome, regardless
of whether Wrch-1 is a direct or indirect target of Src kinase
activity. It will certainly also be of interest to determine which
phosphatase(s) contributes to restoration of the unphosphor-
ylated state of Wrch-1.
Our observations identify important contributors to Wrch-1
regulation and lend further credence to the emerging para-
digm that C-terminal phosphorylation of small GTPases may
serve as a key mechanism to dynamically regulate their local-
ization, activation, and function. Thus, further investigations
into such phosphorylation events will be critical for a better
understanding of the regulation of Rho GTPases.
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